PhIII lung cancer data signals potential approval for AstraZeneca's Imfinzi

The data on AstraZeneca’s Phase III Imfinzi trial is out, and it bodes well for the UK outfit’s bid to get their signature immunotherapy approved for frontline small-cell lung cancer (SCLC).